Plain-English translation of NCT06316076 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This clinical trial is testing a new treatment called (RJMty19), which are specially engineered immune cells designed to reduce harmful B cells that cause autoimmune diseases. The study aims to find the right dose of these cells and determine whether the treatment is safe and effective for people with severe autoimmune diseases like lupus, vasculitis, inflammatory muscle disease, or systemic sclerosis that haven't improved with standard medications. Researchers will carefully monitor participants to see how the medication works in their bodies.
Standard treatments for severe autoimmune diseases don't work for everyone, and some patients have serious side effects or don't respond well enough. This medication represents a completely new approach — using the body's own immune system in a new way to control the disease.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive a one-time infusion of the specially engineered immune cells after receiving chemotherapy to prepare your body. The study is designed as a dose-escalation trial, meaning early participants receive lower doses and later participants may receive higher doses as researchers determine what is safe and effective. You will have regular follow-up visits and blood tests to monitor how you respond to the treatment and watch for any side effects.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
RenJi Hospital
Collaborators
Guangdong Ruishun Biotech Co., Ltd
Enrollment target
~48 participants
Started
October 2023
Primary completion
June 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in March 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Qiong Fu, MD, PhD
RenJi Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.